MEDSNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31
DataMeds AI, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026
$2.67+0.04 (+1.52%)
Close on Oct 19, 2026
- Market cap
- $6.87M
- P/E (TTM)
- –
- Dividend yield
- –
DataMeds AI, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | % of revenue | YoY |
|---|---|---|---|---|
| Product [Member] | $21.87M | $17.67M | 93.7% | +23.8% |
| Pharmacy Retail Sales [Member] | $865.70K | $352.36K | 3.7% | +145.7% |
| Third Party Logistics Services [Member] | $603.42K | $107.00K | 2.6% | +463.9% |
By region
From the segment and revenue-disaggregation notes of DataMeds AI's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.